Discovery of a new chemical scaffold for the treatment of superbug Candida auris infections

References

• Fisher MC, Hawkins NJ, Sanglard D, et al. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739–742.
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.
   PubMed Web of Science ®Google Scholar
• Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017;3(4):57–86.
   PubMedGoogle Scholar
• Denning DW, Bromley MJ. Infectious disease. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–1416.
   PubMed Web of Science ®Google Scholar
• Benedict K, Park BJ. Invasive fungal infections after natural disasters. Emerging Infect Dis. 2014;20(3):349–355.
   PubMed Web of Science ®Google Scholar
• Frías-De-León MG, Pinto-Almazán R, Hernández-Castro R, et al. Epidemiology of systemic mycoses in the COVID-19 pandemic. J Fungi (Basel). 2021;7(7):556–582.
   PubMedGoogle Scholar
• Enoch DA, Yang H, Aliyu SH, et al. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65.
   PubMedGoogle Scholar
• Lee Y, Puumala E, Robbins N, et al. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem Rev. 2021;121(6):3390–3411.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–S94.
   PubMedGoogle Scholar
• Brunke S, Mogavero S, Kasper L, et al. Virulence factors in fungal pathogens of man. Curr Opin Microbiol. 2016;32:89–95.
   PubMed Web of Science ®Google Scholar
• Wu S, Wang Y, Liu N, et al. Tackling fungal resistance by biofilm inhibitors. J Med Chem. 2017;60(6):2193–2211.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Montravers P, et al. What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother. 2018;73(Suppl 1):i14–i25.
   PubMedGoogle Scholar
• Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–44.
   PubMed Web of Science ®Google Scholar
• Rhodes J, Fisher MC. Global epidemiology of emerging Candida auris. Curr Opin Microbiol. 2019;52:84–89.
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Berman J, Novikov A, et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerging Infect Dis. 2017;23(1):195–203.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290.
   PubMed Web of Science ®Google Scholar
• Navalkele BD, Revankar S, Chandrasekar P. Candida auris: a worrisome, globally emerging pathogen. Expert Rev Anti-Infect Ther. 2017;15(9):819–827.
   PubMed Web of Science ®Google Scholar
• Osei Sekyere J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 2018;7(4):e00578.
   PubMed Web of Science ®Google Scholar
• Revie NM, Iyer KR, Robbins N, et al. Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol. 2018;45:70–76.
   PubMed Web of Science ®Google Scholar
• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e392.
   PubMed Web of Science ®Google Scholar
• Tu J, Liu N, Huang Y, et al. Small molecules for combating multidrug-resistant superbug Candida auris infections. Acta Pharm Sin B. 2022;12(11):4056–4074.
   PubMed Web of Science ®Google Scholar
• Oliver JD, Sibley GEM, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA. 2016;113(45):12809–12814.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Fukuda Y, Mitsuyama J, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemother. 2017;72(6):1709–1713.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Shaw KJ, et al. Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis. Antimicrob Agents Chemother. 2019;63(11):e01120–19.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N, Angulo D, et al. Efficacy of ibrexafungerp (SCY-078) against Candida auris in an in vivo Guinea pig cutaneous infection model. Antimicrob Agents Chemother. 2020;64(10):e00854–20.
   PubMed Web of Science ®Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–616.
   PubMed Web of Science ®Google Scholar
• Tu J, Li Z, Jiang Y, et al. Discovery of carboline derivatives as potent antifungal agents for the treatment of cryptococcal meningitis. J Med Chem. 2019;62(5):2376–2389.
   PubMed Web of Science ®Google Scholar
• Pries V, Cotesta S, Riedl R, et al. Advantages and challenges of phenotypic screens: The identification of two novel antifungal geranylgeranyltransferase I inhibitors. J Biomol Screening. 2016;21(3):306–315.
   PubMedGoogle Scholar
• Romo JA, Pierce CG, Chaturvedi AK, et al. Development of anti-virulence approaches for candidiasis via a novel series of small-molecule inhibitors of Candida albicans filamentation. mBio. 2017;8(6):e01991-17.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Y, Liu W, et al. Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation. ACS Med Chem Lett. 2014;5(5):506–511.
   PubMed Web of Science ®Google Scholar
• Romera D, Aguilera-Correa JJ, Gadea I, et al. Candida auris: a comparison between planktonic and biofilm susceptibility to antifungal drugs. J Med Microbiol. 2019;68(9):1353–1358.
   PubMed Web of Science ®Google Scholar
• Li DD, Zhao LX, Mylonakis E, et al. In vitro and in vivo activities of pterostilbene against Candida albicans biofilms. Antimicrob Agents Chemother. 2014;58(4):2344–2355.
   PubMed Web of Science ®Google Scholar
• Yang W, Tu J, Ji C, et al. Discovery of piperidol derivatives for combinational treatment of azole-resistant candidiasis. ACS Infect Dis. 2021;7(3):650–660.
   PubMed Web of Science ®Google Scholar
• Ni T, Li R, Xie F, et al. Synthesis and biological evaluation of novel 2-aminonicotinamide derivatives as antifungal agents. ChemMedChem. 2017;12(4):319–326.
   PubMed Web of Science ®Google Scholar
• Ruiz G B, Lorenz A. What do we know about the biology of the emerging fungal pathogen of humans Candida auris? Microbiol Res. 2021;242:126621–126634.
   PubMedGoogle Scholar
• McLellan CA, Whitesell L, King OD, et al. Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity. ACS Chem Biol. 2012;7(9):1520–1528.
   PubMed Web of Science ®Google Scholar
• Liu N, Tu J, Dong G, et al. Emerging new targets for the treatment of resistant fungal infections. J Med Chem. 2018;61(13):5484–5511.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Fujita M. Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling. J Lipid Res. 2016;57(1):6–24.
   PubMed Web of Science ®Google Scholar
• Yu S, Guo Z, Johnson C, et al. Recent progress in synthetic and biological studies of GPI anchors and GPI-anchored proteins. Curr Opin Chem Biol. 2013;17(6):1006–1013.
   PubMed Web of Science ®Google Scholar
• Victoria GS, Kumar P, Komath SS. The Candida albicans homologue of PIG-P, CaGpi19p: gene dosage and role in growth and filamentation. Microbiology (Reading). 2010;156(10):3041–3051.
   PubMedGoogle Scholar
• Mann PA, McLellan CA, Koseoglu S, et al. Chemical genomics-based antifungal drug discovery: targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis. ACS Infect Dis. 2015;1(1):59–72.
   PubMed Web of Science ®Google Scholar
• Tsukahara K, Hata K, Nakamoto K, et al. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol Microbiol. 2003;48(4):1029–1042.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Duncanson FP, Diekema DJ, et al. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56(1):352–357.
   PubMed Web of Science ®Google Scholar
• Du H, Bing J, Hu T, et al. Candida auris: epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16(10):e1008921.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Magnasco L, Sepulcri C, et al. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections. Expert Rev Clin Pharmacol. 2021;14(10):1205–1220.
   PubMed Web of Science ®Google Scholar
• Cheng YS, Roma JS, Shen M, et al. Identification of antifungal compounds against multidrug-resistant Candida auris utilizing a high-throughput drug-repurposing screen. Antimicrob Agents Chemother. 2021;65(4):e01305–20.
   PubMed Web of Science ®Google Scholar
• de Oliveira HC, Monteiro MC, Rossi SA, et al. Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris. Front Cell Infect Microbiol. 2019;9:83–93.
   PubMed Web of Science ®Google Scholar
• Wall G, Chaturvedi AK, Wormley FL, Jr., et al. Screening a repurposing library for inhibitors of multidrug-resistant Candida auris identifies ebselen as a repositionable candidate for antifungal drug development. Antimicrob Agents Chemother. 2018;62(10):e01084-18.
   PubMed Web of Science ®Google Scholar
• Wang S, Jiang Y, Wu S, et al. Meeting organocatalysis with drug discovery: asymmetric synthesis of 3,3'-spirooxindoles fused with tetrahydrothiopyrans as novel p53-MDM2 inhibitors. Org Lett. 2016;18(5):1028–1031.
   PubMed Web of Science ®Google Scholar
• Billamboz M, Fatima Z, Hameed S, et al. Promising drug candidates and new strategies for fighting against the emerging superbug Candida auris. Microorganisms. 2021;9(3):634–674.
   PubMed Web of Science ®Google Scholar
• Liu N, Wang C, Su H, et al. Strategies in the discovery of novel antifungal scaffolds. Future Med Chem. 2016;8(12):1435–1454.
   PubMed Web of Science ®Google Scholar
• Gauwerky K, Borelli C, Korting HC. Targeting virulence: a new paradigm for antifungals. Drug Discov Today. 2009;14(3):214–222.
   PubMed Web of Science ®Google Scholar
• Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017;16(7):457–471.
   PubMed Web of Science ®Google Scholar
• Paudyal A, Vediyappan G. Cell surface expression of Nrg1 protein in Candida auris. J Fungi (Basel). 2021;7(4):262–276.
   PubMedGoogle Scholar
• Klis FM, de Groot P, Hellingwerf K. Molecular organization of the cell wall of Candida albicans. Med Mycol. 2001;39(Suppl 1):1–8.
   PubMed Web of Science ®Google Scholar
• Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. Bioessays. 2006;28(8):799–808.
   PubMed Web of Science ®Google Scholar
• McKenzie CG, Koser U, Lewis LE, et al. Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages. Infect Immun. 2010;78(4):1650–1658.
   PubMed Web of Science ®Google Scholar
• West L, Lowman DW, Mora-Montes HM, et al. Differential virulence of Candida glabrata glycosylation mutants. J Biol Chem. 2013;288(30):22006–22018.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zou Y, Chen X, et al. Innate immune responses against the fungal pathogen Candida auris. Nat Commun. 2022;13(1):3553–3573.
   PubMed Web of Science ®Google Scholar